Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:RTRX Travere Therapeutics (RTRX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisCompetitorsHeadlinesTrends About Travere Therapeutics Stock (NASDAQ:RTRX) 30 days 90 days 365 days Advanced Chart Ad Stansberry Research2025 could be “worse than the dot-com bust”, says man who predicted 2008 banking crisisDan is sharing his latest work with the public. Because what he's tracking right now, he says, is too serious to keep private.Click here to see Dan's full warning to the public. Get Travere Therapeutics alerts:Sign Up Key Stats Today's Range$17.13▼$17.8850-Day Range$24.25▼$28.1852-Week Range$8.98▼$24.96Volume3.70 million shsAverage Volume412,277 shsMarket Capitalization$877.07 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewTravere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.Read More… Receive RTRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Travere Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address RTRX Stock News HeadlinesKidney Disease Leader Travere Therapeutics Pulls Back To Key LevelNovember 20, 2024 | msn.comTravere Therapeutics 7.81M share Spot Secondary priced at $16.00November 8, 2024 | markets.businessinsider.comWall Street Icon: “You must get on the right side of this thing”I created one of the first quantitative analysis-based stock picking systems long before "quants" became a thing on Wall Street… leading Forbes to call me "King of the Quants." I'm writing to you today because my system has recently uncovered a market phenomenon I haven't seen in 30 years.December 22, 2024 | InvestorPlace (Ad)Travere Therapeutics announces common stock offering, no amount givenNovember 7, 2024 | markets.businessinsider.comTravere Therapeutics (TVTX) Gets a Buy from TD CowenNovember 6, 2024 | markets.businessinsider.comTravere Therapeutics: Strong Growth and Strategic Advancements Drive Buy RatingNovember 2, 2024 | markets.businessinsider.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Q3 2024 Earnings Call TranscriptNovember 1, 2024 | msn.comTravere Therapeutics price target raised to $27 from $23 at ScotiabankNovember 1, 2024 | markets.businessinsider.comSee More Headlines RTRX Stock Analysis - Frequently Asked Questions How were Travere Therapeutics' earnings last quarter? Travere Therapeutics, Inc. (NASDAQ:RTRX) released its earnings results on Thursday, November, 5th. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.59) by $0.15. Travere Therapeutics had a negative trailing twelve-month return on equity of 36.38% and a negative net margin of 49.13%. What other stocks do shareholders of Travere Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Travere Therapeutics investors own include CVS Health (CVS), Bristol-Myers Squibb (BMY), Gilead Sciences (GILD), Novavax (NVAX), TG Therapeutics (TGTX), Dynavax Technologies (DVAX) and Intercept Pharmaceuticals (ICPT). Company Calendar Last Earnings11/05/2020Today12/21/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:RTRX CUSIPN/A CIK1438533 Webwww.retrophin.com Phone(888) 969-7879FaxN/AEmployees221Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($3.46) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-146,430,000.00 Net Margins-49.13% Pretax MarginN/A Return on Equity-36.38% Return on Assets-14.90% Debt Debt-to-Equity Ratio0.66 Current Ratio7.23 Quick Ratio7.14 Sales & Book Value Annual Sales$175.34 million Price / Sales5.00 Cash FlowN/A Price / Cash FlowN/A Book Value$5.15 per share Price / Book3.34Miscellaneous Outstanding Shares51,052,000Free FloatN/AMarket Cap$877.07 million OptionableNot Optionable Beta0.67 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.Get This Free Report This page (NASDAQ:RTRX) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredMUST SEE: The most important video in the world right now?If you have a significant amount of money in the stock market right now — or if you're sitting on the sideline...InvestorPlace | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Travere Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Travere Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RTRX Stock Alerts